Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T17687
|
||||
| Former ID |
TTDR00314
|
||||
| Target Name |
Fibroblast growth factor receptor
|
||||
| Synonyms |
FGF receptor
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10: C00-C75, C7A, C7B, D10-D36, D3A] | |||||
| Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
| Drugs and Mode of Action | |||||
| Drug(s) | PD173074 | Drug Info | Phase 2 | Discovery agent | [1], [2] |
| TAS-120 | Drug Info | Phase 1/2 | Multiple myeloma | [3] | |
| BAY1163877 | Drug Info | Phase 1 | Cancer | [4] | |
| Debio 1347 | Drug Info | Phase 1 | Late-stage solid tumors | [5] | |
| PD166866 | Drug Info | Terminated | Discovery agent | [6] | |
| Modulator | ARO 087 | Drug Info | [7] | ||
| Debio 1347 | Drug Info | [8] | |||
| Antagonist | BAY1163877 | Drug Info | [9] | ||
| PD166866 | Drug Info | [10] | |||
| PD173074 | Drug Info | [10] | |||
| SU4984 | Drug Info | [10] | |||
| SU5403 | Drug Info | [10] | |||
| TAS-120 | Drug Info | [11] | |||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5037). | ||||
| REF 2 | ClinicalTrials.gov (NCT01441297) BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
| REF 3 | ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health. | ||||
| REF 4 | ClinicalTrials.gov (NCT01976741) Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor. U.S. National Institutes of Health. | ||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037338) | ||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009865) | ||||
| REF 7 | J Clin Oncol 33, 2015 (suppl; abstr 2545). | ||||
| REF 8 | The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58. | ||||
| REF 9 | Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739. | ||||
| REF 10 | Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. | ||||
| REF 11 | TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.